Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections

Collapse authors list.
Blair, J, Gregory, JW, Hughes, D ORCID: 0000-0001-8247-7459, Ridyard, CH, Gamble, C ORCID: 0000-0002-3021-1955, McKay, A ORCID: 0000-0003-1312-8911, Didi, M, Thornborough, K, Bedson, E ORCID: 0000-0001-5209-1854, Awoyale, L et al (show 2 more authors) , Cwiklinski, E and Peak, M ORCID: 0000-0003-1909-3211 (2015) Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections Trials, 16 (1). 163-. ISSN 1745-6215, 1745-6215

Access the full-text of this item by clicking on the Open Access link.

Text Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections.pdf - Published version Download (485kB)

Abstract

Background: Intensive insulin therapy with continuous subcutaneous insulin infusion (CSII) devices or multiple daily injections (MDI) reduces the risk of long-term vascular complications of type I diabetes (TID). Both treatments are used routinely, but there is little evidence to demonstrate superiority of either treatment. If CSII treatment reduces the risk of long-term complications or is associated with an improved quality of life (QoL), the additional cost of this therapy may be compensated for by a reduction in long-term health expenditure. If there is no demonstrable difference between treatments, health-care resources may be better invested elsewhere. This study aims to address this gap in knowledge. Methods/design: This is a pragmatic, randomised controlled trial (RCT). Fifteen centres, selected to represent a population with a broad demographic, will recruit 316 patients, newly diagnosed with TID, aged between 7 months and 15 years. Exclusion criteria include additional pathologies or treatments likely to affect glycaemic control and a first-degree relative with TID. Randomisation to CSII or MDI is stratified for age, gender and recruiting centre. The randomised treatment starts within 15 days of diagnosis. Patients will be trained to adjust their insulin dose according to carbohydrate intake and blood glucose level. Discussion: This is the first adequately powered RCT comparing CSII and MDI in a non-selected population, treated according to standard practice guidelines. It will produce data that are meaningful to individual patients and local and national policymakers.

Item Type:	Article
Uncontrolled Keywords:	Type I diabetes, Child, Infant, Insulin pump, Multiple daily insulin injections, Randomised controlled trial
Depositing User:	Symplectic Admin
Date Deposited:	31 Oct 2018 11:25
Last Modified:	01 Mar 2026 01:16
DOI:	10.1186/s13063-015-0658-5
Open Access URL:	https://trialsjournal.biomedcentral.com/track/pdf/...
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3028186
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.